{"organizations": [], "uuid": "a72e079ca3b4ca59f51d5e9daeddb24e0dd72e52", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-moderna-and-merck-expand-mrna-canc/brief-moderna-and-merck-expand-mrna-cancer-vaccines-collaboration-idUSB8N1LI03L", "country": "US", "domain_rank": 408, "title": "BRIEF-Moderna And Merck Expand MRNA Cancer Vaccines Collaboration", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-05-04T00:58:00.000+03:00", "replies_count": 0, "uuid": "a72e079ca3b4ca59f51d5e9daeddb24e0dd72e52"}, "author": "", "url": "https://www.reuters.com/article/brief-moderna-and-merck-expand-mrna-canc/brief-moderna-and-merck-expand-mrna-cancer-vaccines-collaboration-idUSB8N1LI03L", "ord_in_thread": 0, "title": "BRIEF-Moderna And Merck Expand MRNA Cancer Vaccines Collaboration", "locations": [], "entities": {"persons": [{"name": "merck", "sentiment": "none"}], "locations": [], "organizations": [{"name": "reuters) - merck & co inc", "sentiment": "none"}, {"name": "merck - co", "sentiment": "none"}, {"name": "reuters staff", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "associated", "sentiment": "none"}, {"name": "merck", "sentiment": "none"}, {"name": "moderna", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 3 (Reuters) - Merck & Co Inc:\n* MODERNA AND MERCK EXPAND MRNA CANCER VACCINES COLLABORATION\n* MERCK SAYS EXPANSION INCLUDES JOINT DEVELOPMENT OF MODERNAâ€™S KRAS ONCOGENE PROGRAM, OTHER POTENTIAL MRNA CANCER VACCINES\n* MERCK SAYS CO WILL MAKE $125 MILLION INVESTMENT IN MODERNA IN NEWLY PRICED SERIES H PREFERRED EQUITY\n* MERCK - CO, MODERNA TO NOW ADVANCE JOINTLY MRNA-5671 IN HUMAN STUDIES, PLAN TO CONDUCT COMBINATION STUDIES WITH ADDITIONAL IMMUNO-ONCOLOGY THERAPIES\n* MERCK - CO TO BE RESPONSIBLE FOR CLINICAL DEVELOPMENT OF MRNA-5671, ASSOCIATED COSTS; MODERNA TO BE RESPONSIBLE FOR CLINICAL SUPPLY, ASSOCIATED COSTS\n* MERCK - FOLLOWING HPOC STUDIES, CO MAY OPT-IN ON FURTHER DEVELOPMENT, COMMERCIALIZATION OF MRNA-5671 UPON PAYMENT OF UNDISCLOSED FEE TO MODERNA\n* MERCK SAYS FOLLOWING OPT-IN, PARTIES WILL SHARE EQUALLY GLOBAL NET PROFITS, COSTS ASSOCIATED WITH MRNA-5671 Source text for Eikon:\nOur ", "external_links": [], "published": "2018-05-04T00:58:00.000+03:00", "crawled": "2018-05-04T01:14:59.026+03:00", "highlightTitle": ""}